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  Chapter  9    
NO LONG-TERM EFFECTS OF STIMULANT 
TREATMENT ON ADHD SYMPTOMS, SOCIAL-
EMOTIONAL FUNCTIONING, OR COGNITION 
                                                         Submitted  as:  Schweren  LJS,  Hoekstra  PJ,  van  Lieshout  M,  Oosterlaan  J,  Rommelse  NNJ,  Buitelaar  JK,  Franke  B,  Hartman  CA.  Long-­‐term  effects  of  stimulant  treatment  on  ADHD  symptoms,  social-­‐emotional  functioning,  and  cognition.    
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ABSTRACT   Background:   Methodological   and   ethical   constraints   have   hampered   research   into  lasting   long-­‐term   outcomes   of   stimulant   treatment   in   individuals   with   attention-­‐deficit/hyperactivity  disorder  (ADHD).    Aims:   To   investigate   whether   stimulant   treatment   history   predicts   long-­‐term  development   of   ADHD   symptoms,   social-­‐emotional   functioning,   or   cognition,  measured  after  medication  wash-­‐out.  Method:   Outcomes   were   measured   twice,   six   years   apart,   in   two   ADHD   groups  (stimulant-­‐treated  vs.  not  stimulant-­‐treated  between  baseline  and  follow-­‐up),  closely  matched   on   baseline   characteristics   (n=148,   58%   male,   age=11.1).   A   matched  healthy  control  group  was  included  for  reference.    Results:  All  but  two  outcome  measures  (emotional  problems  and  prosocial  behavior)  improved  between  baseline  and  follow-­‐up.  For  all  outcomes,  improvement  over  time  was  the  same  for  participants  who  had  received  treatment  and  those  who  had  not.    Conclusions:  Stimulant  treatment  is  not  associated  with  the  long-­‐term  developmental  course  of  ADHD  symptoms,  social-­‐emotional  functioning,  or  cognition.  These  findings  are  an  important  source  to  feed  the  scientific  and  public  debate.           
165     




METHODS   Participants    Participants   were   drawn   from   the   prospective   multi-­‐centre   IMAGE-­‐NeuroIMAGE   cohort   study   (von   Rhein   et   al.,   2015a).   The   full   cohort   includes   751  children,   adolescents,   and   young   adults   with   ADHD   from   590   families.   At   baseline,  ADHD   diagnosis  was   ascertained   using   the   Strengths   and   Difficulties   Questionnaire  (van  Widenfelt  et  al.,  2003)  (SDQ,  >90th  percentile  on  the  hyperactivity  subscale),  the  parent-­‐  and  teacher-­‐rated  Conners’  ADHD  scales  (CPRS  and  CTRS;  T≥63  on  the  DSM  inattentive   or   hyperactive/impulsive   scale)   (Conners   et   al.,   1998a,   1998b)   and   the  Parental  Account  of  Children’s  Symptoms  interview  (PACS;  ≥6  symptoms,  present  in  ≥2  situations  and  ≥1  symptom  reported  by  the  teacher)  (Taylor,  1986).  Participants  with   ≥6   symptoms   but  who   did   not   fulfill   all   diagnostic   criteria,   were   classified   as  subthreshold   ADHD.   At   follow-­‐up,   ADHD   diagnosis   in   participants   <18   years   was  ascertained   again   using   the   same   CPRS   and   CTRS   criteria,   complemented   with   the  Schedule  for  Affective  Disorders  and  Schizophrenia  for  School-­‐Age  Children  interview  (K-­‐SADS;   ≥6   symptoms,   present   in   ≥2   situations,   causing   impairment,   and   onset  before   age   12)   (Kaufman   et   al.,   1997).   For   participants   ≥18   years,   the   self-­‐rated  Conners’   scale   (CAARS;   Conners   et   al.,   1999)  was   used   instead   of   the   teacher-­‐rated  scale,  and  five  symptoms  were  sufficient  for  diagnosis.  Participants  who  scored  T≥63  on   either   of   the   Conners’   scales   or   had   sufficient   symptoms,   but   did   not   fulfill   all  diagnostic  criteria,  were  classified  as  subthreshold  ADHD.    Average   follow-­‐up   time  was  5.9  years   (SD=0.6),   and   the   retention   rate  was  high  (77%).  We  applied  the  following  inclusion  criteria:  (1)  participation  at  baseline  and  follow-­‐up,  (2)  diagnosis  of  (subthreshold)  ADHD  at  baseline  and/or  at  follow-­‐up,  (3)   IQ>70   at   baseline   and   follow-­‐up,   and   (4)   no   known   genetic   or   neurological  disorders.   Eligible   participants   were   split   according   to   treatment   between   baseline  and  follow-­‐up  into  stimulant-­‐treated  (n=337)  and  non-­‐stimulant-­‐treated  participants  (n=138).   Stimulant   treatment   prior   to   baseline   and   treatment   with   non-­‐stimulant  psychoactive  medication  was  allowed  in  both  groups.  From  the  two  ADHD  groups  we  selected  all  participants  who  had  a  one-­‐to-­‐one  match  on  gender,  age  (±<0.5  SD),  and  baseline   number   of   ADHD   symptoms   (±<0.5   SD).   This   resulted   in   two   comparable  groups  of  74  participants  with  ADHD  each  (Table  1).  For  reference,  a  gender-­‐  and  age-­‐matched  healthy  control  sample  was  drawn  from   the   IMAGE-­‐NeuroIMAGE   cohort   as   well,   applying   the   same   inclusion   and  matching   criteria   (except   inclusion   criterion   two/symptom-­‐matching).   In   addition,  control  participants  had  no  family-­‐history  of  any  psychiatric  disorder.  All  assessments  took  place  at  two  sites  in  the  Netherlands.  Participants  were  asked  to  withhold  use  of  
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psychoactive   drugs   for   48   hours   before   each   assessment.   Informed   consent   was  signed  by  all  participants  and  their  parents  (only  parents  signed  informed  consent  for  participants  <  12  years).  Procedures  were  approved  by  the  local  ethical  committee  of  each  site.    
 
TABLE 1.  Baseline  characteristics  of  the  two  treatment  groups.  
   Treated   Non-­‐treated        
   M   SD   M   SD   Stat.    p  Gender=male   N=43   58.1%   N=43   58.1%   0.000   1.000  Age   11.14   3.29   11.00   3.23   0.066   0.798  Site=Amsterdam   N=27   36.5%   N=46   62.2%   9.759   0.002*  IQ   99.93   10.47   103.55   10.77   3.605   0.060  Socio-­‐economic  status   11.26   2.02   12.07   2.52   4.522   0.035*  Follow-­‐up  interval  (years)   5.92   0.60   5.86   0.68   0.258   0.613  Treatment  prior  to  baseline=yes   N=52   70.3%   N=18   24.3%   31.335   <0.001*  ADHD  type               8.677   0.070  Unaffected   N=6   8.1%   N=7   9.5%        Inattentive   N=4   5.4%   N=6   8.1%        Hyperactive   N=1   1.4%   N=2   2.7%        Combined   N=55   74.3%   N=39   52.7%        Subthreshold   N=8   10.8%   N=20   27.0%        Comorbid  problems  #                    Anxiety/shyness   5.20   4.92   4.30   4.47   1.333   0.250  Perfectionism   3.85   4.24   3.55   3.55   0.214   0.644  Psychosomatic  problems   3.45   3.33   2.80   3.16   1.445   0.231  Stat  =  Chi2  for  categorical  variables,  student-­‐t  for  continuous  variables.  #  scores  on  the  anxiety/shyness  scale,  perfectionism  scale,  and  psychosomatic  problems  scale  of  the  parent-­‐  and  teacher-­‐rated  Conners’  questionnaires  were  used  as  a  proxy  of  baseline  comorbid  problems.  *  =  significant  difference  between  treated  and  non-­‐treated  participants.        
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Stimulant  treatment     Participants   and   parents   provided   written   consent   to   request   prescription  records   from   their   pharmacies.   In   addition,   they   reported   lifetime   history   of  psychoactive   medication   in   a   questionnaire   at   follow-­‐up   measurement.   Pharmacy  data  covering   the  baseline-­‐follow-­‐up   interval  were  available   for  91%  of  participants  with   ADHD   (n=135).   Participants   were   classified   as   stimulant-­‐treated   if   they   had  been  prescribed  any  immediate  or  extended  release  methylphenidate  preparations,  or  d-­‐amphetamine   preparations,   between   baseline   and   follow-­‐up.   When   pharmacy  transcripts  were  not  available  or   incomplete  (n=13),   treatment  history  was  derived  from   the   questionnaire   data.   The   questionnaire   data   was   also   used   to   determine  stimulant   treatment  prior   to  baseline  (“previously   treated”  or   “stimulant-­‐naïve”)   for  all  participants.          Outcome  measures    Parent-­‐rated  numbers  of  hyperactivity-­‐impulsivity  and  inattention  symptoms  were  measured  at  baseline  and   follow-­‐up  using   the  respective  DSM  subscales  of   the  CPRS  (range  0:27).  For  participants  using  medication,  parents   rated  behavior   in   the  participant’s   non-­‐medicated   state.   Four   indicators   of   social-­‐emotional   functioning  were  derived  from  the  SDQ  for  both  time  points:  problems  with  emotion  regulation,  problems  with  peer  relationships,  conduct  problems,  and  prosocial  behavior  (range  0-­‐10).   In  addition,  six  cognitive  tests  were  administered  at  both  baseline  and  follow-­‐up.  Three  tasks  measured  motor  control:  Baseline  Speed,   in  which  participants  were  required  to  press  a  key  upon  unpredictable  appearance  of  a  stimulus;  Pursuit,  where  participants   followed   a   randomly   moving   target   with   the   cursor   as   precisely   as  possible;   and   Tracking,   in   which   participants   were   required   to   trace   an   invisible  midline   between   an   inner   and   an   outer   circle   as   precisely   as   possible.   Two   tasks  measured   timing:  Time  Estimation,  where  participants  were  asked   to  reproduce   the  duration   of   visually   presented   stimuli   of   different   lengths   (4,   8,   12,   16,   and   20  seconds);   and   Motor   Timing,   in   which   participants   were   instructed   to   produce   1-­‐second   intervals   as   accurately   as   possible.   Working   memory   was   assessed   in   the  backwards  condition  of  the  Digit  Span  test  (WISC-­‐III/WAIS-­‐III),  in  which  participants  had   to   reproduce   an   increasingly   long   sequence   of   numbers   in   reverse   order.   For  details,  see  Supplementary  Table  1.        
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Statistical  analyses    We   used   linear   mixed   effects   models,   predicting   symptoms   of  hyperactivity/impulsivity  and  inattention,  each  of  the  four  social-­‐emotional  outcomes,  and  performance  on  each  cognitive  test  from  time  (baseline  or  follow-­‐up),  treatment  (“stimulant-­‐treated”  or  “not  stimulant-­‐treated”  during  the  study  phase),  and  time-­‐by-­‐treatment-­‐interaction.   The   effect   of   interest   is   captured   in   the   time-­‐by-­‐treatment  interaction,  which  evaluated  whether  the  outcome  variables  changed  differently  over  time   for   the   stimulant-­‐treated   group   compared   to   the   non-­‐treated   group.   Baseline  demographic/clinical  between-­‐group  differences  were  included  as  covariates,  as  was  a  random   intercept  per   family   to  account   for  dependencies  among  siblings.  Multiple  testing  was   accounted   for   by   Bonferroni   adjustment:   alpha  was   divided   by   two   for  ADHD   symptoms   (α=0.05/2=0.025),   by   four   for   social-­‐emotional   outcomes  (α=0.012),  and  by  six  for  cognitive  outcomes  (α=0.008).    Previous  work  by  our  group  described  changes  over  time  in  ADHD  symptoms  and  cognitive  functioning  in  participants  with  ADHD  compared  to  typically  developing  participants  (van  Lieshout  et  al.,  2016a;  2016b).  Case-­‐control  differences  are  thus  not  the   focus   of   the   current   study.   Rather,   the   matched   control   group   was   used   as   a  reference  group  for  normative  developmental  changes.  For  visualization  of  estimated  marginal  means  of  all  groups  (stimulant-­‐treated,  not  stimulant-­‐treated,  and  control),  the   models   described   above   were   re-­‐estimated   across   all   participants   with   a   fixed  factor  for  group.  Sensitivity   analyses  were   performed   to   test   the   robustness   of   our   findings.  With  a  relatively  short  wash-­‐out  time  (48h),  immediate  withdrawal  effects  may  have  affected  cognitive  functioning  in  participants  who  received  ongoing  treatment  at  time  of   measurement.   Therefore,   analyses   were   repeated   with   an   additional   covariate  encoding  whether  participants  were  actively  being  treated  with  stimulants  within  six  months   prior   to   assessment   or   not,   and   its   interaction   with   the   effect   of   interest  (active   treatment   *   time   *   treatment   between   baseline   and   follow-­‐up).   Second,   all  analyses  were   repeated  with  baseline  age  as   an  additional  predictor,   to   address   the  wide  age-­‐range  within  our  sample.  Here,  change  over  time  in  each  outcome  variable  was  predicted  from  age-­‐by-­‐treatment  interaction,  thus  analyzing  whether  the  effect  of  treatment  on  clinical/social-­‐emotional/cognitive  changes  over  time  was  different  for  participants  of  different  ages.      
RESULTS    Mean  age  of  participants  with  ADHD  was  11.1  years  (SD=3.2)  at  baseline  and  17.0   years   (SD=3.3)   at   follow-­‐up.   Fifty-­‐eight   percent   of   participants   was   male.  
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Participants  were  diagnosed  with  ADHD  or  subthreshold  ADHD  at  baseline   (n=135,  91.2%)   and/or   at   follow-­‐up   (n=132,   89.2%).   Most   participants   reached   diagnostic  criteria   at   both   times   (n=119,   80.41%).   Fifteen   participants   (10.1%)   with  subthreshold   ADHD   never   met   criteria   for   full   ADHD   diagnosis.   At   baseline,   the  majority  of  participants  had  combined  type  ADHD  (n=94,  63.5%),  while  at  follow-­‐up  the   majority   had   either   combined   type   (n=40,   27.0%)   or   inattentive   type   (n=51,  34.5%),  with  no  differences  between  groups  (Table  1).  Within  the  stimulant-­‐treated  group,  average  cumulative  stimulant  dose  between  baseline  and  follow-­‐up  was  43336  mg,   which   equals   5.9   years   of   20.1   mg   per   day.   Forty   participants   (54.1%)   had  received  active  stimulant  treatment  within  six  months  prior  to  follow-­‐up  assessment;  the   other   participants   had   ceased   stimulant   treatment   earlier.   Participants   in   the  stimulant-­‐treated  group  had  lower  SES  (p=0.035),  were  more  likely  to  have  received  stimulant  treatment  prior  to  the  initial  assessment  (Chi2=31.335,  p=0.001),  and  more  likely   to   have   received   atomoxetine   treatment   between   baseline   and   follow-­‐up  (nOVERALL=16,   10.8%;   nTREATED=13,   17.6%;   nNON-­‐TREATED=3,   4.1%;   Chi2=6.862,  p=0.009).   There   was   a   site   effect   for   stimulant   treatment   as   well   (Chi2=9.759,  p=0.002).   Site,   SES,   and   prior   treatment   were   therefore   added   as   covariates   in   all  between-­‐group   comparisons.   At   baseline,   the   two   treatment   groups   did   not   differ  from  each  other  with  regard  to  any  of  the  clinical  or  cognitive  outcome  measures.    There  was  a  significant  main  effect  of  time  on  ADHD  symptoms,  as  well  as  on  two  out  of  four  social-­‐emotional  outcome  measures  (Table  2).  Across  all  participants  with   ADHD,   symptoms   of   hyperactivity/impulsivity   and   inattention,   peer   problems,  and  conduct  problems  improved  between  baseline  and  follow-­‐up.  There  were  no  main  effects  of  time  on  emotional  problems  or  prosocial  behavior.  Improvement  over  time  was   also   found   for   performance   on   all   cognitive   tasks:   participants   showed   lower  Baseline   Speed   variability,   smaller   deviations   on   the   Tracking,   Pursuit   and   Time  Estimation  tasks,  and  higher  maximum  Digit  Span  at  follow-­‐up  compared  to  baseline.    There  were   no  main   effects   of   treatment   group,   and   no   time-­‐by-­‐treatment-­‐group  interaction  effects  on  any  of   the  outcome  measures  (Table  2,  Figure  1  and  2).  Thus,   changes   in   ADHD   symptoms,   social-­‐emotional   and   cognitive   functioning   over  time   were   the   same   for   participants   who   received   stimulant   treatment   between  baseline  and  follow-­‐up  and  those  who  had  not.  Moreover,  changes  over  time  were  the  same   for   participants   on   active   stimulant   treatment   at   follow-­‐up   assessment   and  those  who  were  not,  suggesting  no  confounding  by  withdrawal  effects.  Finally,   there  were   no   significant   interactions   with   age,   suggesting   that   treatment   effects   were  similar  at  different  ages.      
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TABLE 2.  Baseline  and  follow-­‐up  scores  across  treatment  groups,  and  the  effects  of  time,  treatment,  and  time-­‐by-­‐treatment  interaction.  
   Baseline   Follow-­‐up           
   EMM   SD   EMM   SD   pTIME   pTREATMENT   PTIME*TREATMENT  Hyper/imp  symptoms   14.22   5.95   11.83   6.73   <0.001*   0.212   0.188  Inattention  symptoms   12.28   6.15   7.38   5.55   <0.001*   0.557   0.054  Emotional  problems   2.98   3.00   2.82   3.08   0.736   0.577   0.707  Prosocial  behavior   7.15   2.08   7.38   2.19   0.351   0.280   0.142  Peer  problems   2.82   2.12   2.19   1.98   0.003*   0.382   0.424  Conduct  problems   3.09   2.00   2.43   1.83   0.002*   0.238   0.906  Baseline  Speed  variability   172.37   103.89   90.29   50.35   <0.001*   0.513   0.672  Pursuit  (inaccuracy)   6.44   3.74   3.87   0.76   <0.001*   0.609   0.320  Tracking  (inaccuracy)   2.85   1.81   1.34   0.94   <0.001*   0.798   0.175  Motor  Timing  (inaccuracy)   203.11   95.10   148.83   51.48   <0.001*   0.449   0.341  Time  Estimation  (inaccuracy)   2.72   1.79   1.48   0.81   <0.001*   0.776   0.411  Digit  Span   3.92   1.15   4.49   1.26   <0.001*   0.126   0.715  EMM=estimated  mean  score  across  participants  with  ADHD,  adjusted  for  stimulant  treatment  prior  to  baseline  measurement,  site,  and  SES.  *=p<0.012  or  p<0.008.      




FIGURE 1.   Change   in   ADHD   symptoms   and   social-­‐emotional   outcome   measures   over   ~6   years,   for  stimulant-­‐treated  (grey)  and  non-­‐treated  (black)  participants  with  ADHD,  and  control  participants  (grey  dashed),   matched   on   baseline   age,   gender,   and   ADHD   symptoms.   Baseline   social-­‐emotional   outcomes  were  not  assessed  for  typically  developing  participants.  The  slopes  of  the  two  treatment  groups  did  not  differ  for  any  outcome.    
  
 
FIGURE 2.   Change   in   cognitive   test   performance   over   ~6   years,   for   stimulant-­‐treated   (grey)   and   non-­‐treated  (black)  participants  with  ADHD,  and  control  participants  (grey  dashed),  matched  on  baseline  age,  gender,  and  ADHD  symptoms.  The  slopes  of  the  two  treatment  groups  did  not  differ  for  any  outcome    Interpretation  and  previous  studies     Our  findings  put   into  perspective  previous  studies  reporting  beneficial   long-­‐term   effects   of   stimulant   treatment.   First,   previous   studies   reporting   long-­‐term  beneficial   treatment   effects   oftentimes   assessed   outcomes   when   patients   were   on  active   treatment  (Abikoff  et  al.,  2004;  Charach  et  al.,  2004).  Their   findings  may  thus  
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represent   either   lasting   effects   of   prior   treatment,   transient   effects   of   ongoing  treatment,   or   a   combination   of   both.   Our   findings,   in   conjunction   with   reports   of  better   outcome   during   phases   of   active   stimulant   treatment   (Chang   et   al.,   2016;  Lichtenstein  et  al.,  2012),  suggest   that  previously  reported   long-­‐term  effects  may  be  driven  by  ongoing  transient  effects  rather  than  lasting  effects.  The  absence  of  lasting  treatment  effects  in  our  sample  convenes  with  negative  long-­‐term  findings  of  the  MTA  study,  that  have  previously  been  attributed  to  self-­‐selection  during  the  observational  phase  (Molina  et  al.,  2009;  Swanson  et  al.,  2007a).  Our   findings,  however,  underline  the  possibility  that  the  theorized  long-­‐term  effects  may  in  fact  not  occur.  At  the  same  time,   we   wish   to   emphasize   that   beneficial   long-­‐term   treatment   effects   have   been  found   in   outcomes   that   were   not   addressed   here,   such   as   the   development   of  comorbid  disorders  later  in  life  (Biederman  et  al.,  2009).  Second,  our  findings  are  in  line  with  a  previous  report  of  improved  attention  task   performance   after   a   one-­‐year   stimulant   treatment   episode   even   at   drug-­‐free  status  (Huang  et  al.,  2012),  which,  in  the  absence  of  a  reference  group,  could  indicate  either  lasting  beneficial  treatment  effects  or  improved  cognitive  performance  at  older  age.   In   the   current   study,   changes  over   time  were   the   same   in   the   treated  and  non-­‐treated  groups,  suggesting  that  improvement  over  time  is  not  related  to  treatment.    Third,   several   previous   studies   have   reported   more   severe   and/or   more  persistent   ADHD   in   individuals   who   had   received   stimulant   treatment   during  childhood,  which  could  indicate  either  detrimental  treatment  effects  or  confounding-­‐by-­‐indication  (Biederman  et  al.,  2012;  Molina  et  al.,  2009;  van  Lieshout  et  al.,  2016a).  The   current   findings,   free   of   confounding-­‐by-­‐indication   due   to   stringent   matching  procedures   and   accounting   for   baseline   measurements,   provide   no   evidence   of  detrimental  treatment  effects.         Implications     The  current  findings  are  an  important  source  to  feed  the  scientific  and  public  debate   about   pharmacological   treatment   for   ADHD   that   has   focused   on   long-­‐term  hazards   and   benefits.   First,   our   findings   emphasize   that   the   course   of   ADHD  symptoms   and   related   outcomes   are   not   altered   by   stimulant   treatment.   Previous  work  of  our  group  showed  that  ADHD  symptoms  tend  to  decline  but  not  disappear  at  later   age   (van   Lieshout   et   al.,   2016a).   The   current   results   add   to   these   findings   by  showing   that   this   conclusion   holds   for   both   stimulant-­‐treated   and   non-­‐treated  individuals.   Second,   the   absence   of   long-­‐term   treatment   effects   on   clinical   and  cognitive   outcomes   may   guide   the   interpretation   of   findings   of   structural   brain  changes  associated  with  stimulant   treatment  (or   the  absence  thereof).  The  evidence  for   normalized   brain   structure   in   children  with   ADHD  who   had   received   long-­‐term  
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stimulant   treatment   is  mixed   (Schweren   et   al.,   2015;   Shaw   et   al.,   2009;   2014).   The  absence   of   lasting   treatment   effects   on   a   broad   spectrum   of   clinical/behavioral  outcomes   emphasizes   the   importance   of   investigating   behavioral   correlates   and  clinical  relevance  of  stimulant  effects  on  the  brain.      Strengths  and  limitations       This   is   the   first   longitudinal   study   investigating   long-­‐term   treatment   effects  that  included  a  non-­‐treated  ADHD  and  a  typically  developing  sample  and  reported  on  a  wide   spectrum   of   clinical   and   cognitive   outcomes.   The   average   follow-­‐up   time   of  almost  six  years  allowed  the  detection  of  effects  emerging  at   later  age,  and  captured  the  late  adolescent/early  adulthood  phase  that  is  often  characterized  by  both  clinical  and   normative   developmental   changes,   which   we   were   able   to   tease   apart.   Our  rigorous  one-­‐to-­‐one  matching  procedure  allowed  firm  conclusions.  Finally,  extensive  diagnostic   assessments   resulted   in   a   well-­‐characterized   ADHD   sample,   and   the  availability   of   pharmacy   records   enabled   highly   reliable   assessment   of   treatment  history.     The   current   study   had   limitations   as   well.   Treatment   allocation   was   not  random.   We   were   able   to   rule   out   confounding-­‐by-­‐indication   for   all   measured  baseline   variables,   but   not   for   non-­‐measured   potential   between-­‐group   differences.  Especially   functional   impairment   and   comorbidity   could   not   satisfactorily   be  addressed.  Propensity  score  adjustment  would  have  been  valuable  in  this  regard,  but  was  not  feasible  with  the  available  data.  Confounding  may  also  have  occurred  during  the   study   phase,   e.g.   behavioral   treatment   (not   assessed)   may   have   been   more  common   in   one   group   compared   to   the   other.   Second,   findings   regarding   clinical  outcomes   furthermore   rely   on   reports   by   parents,   who   were   not   blind   to   the  participant´s  treatment  history  or  status.  Third,   the  current  design  did  not  allow  full  investigation   of   treatment   timing,   since   participants   had   often   initiated   treatment  prior   to   the   baseline  measurement   and/or   continued   treatment   after   the   follow-­‐up  measurement.  Treatment  at  different  ages  may  be  associated  with  different  long-­‐term  consequences,  although  in  our  sample  we  found  no  indications  of  such  effects.            
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SUPPLEMENTAL INFORMATION    
TABLE S1.  Neurocognitive  tasks.  Task  (aim)   Description   Performance  measure   n  Baseline  Speed  (motor  output  in  response  to  cue)  
A  white  square  appeared  unpredictably  (500-­‐2500ms  after  response)  on  a  screen,  after  which  participants  were  required  to  press  a  key.  Practiced  and  executed  with  the  non-­‐preferred  hand,  thereafter  with  the  preferred  hand.  
Standard  deviation  of  reaction  times  in  ms  averaged  across  both  hands   78  (52.7%)  
Pursuit  (motor  control  with  continuous  adaptation)  
Participants  were  required  to  ‘catch’  a  randomly  moving  stimulus  (asterisk,  10  mm/second)  as  precisely  as  possible  by  moving  the  cursor  on  top  of  the  stimulus  with  the  left  hand.  
Mean  absolute  distance  in  mm  between  target  and  cursor   81  (54.7%)  
Tracking  (motor  control  without  continuous  adaptation)  
With  the  left  hand,  participants  traced  an  invisible  midline  between  an  inner  and  outer  circle  presented  on  the  screen  (radius  7.5  and  8.5  cm,  respectively),  counterclockwise  and  as  quickly  and  precisely  as  possible.  
Mean  absolute  distance  in  mm  between  target  (midline)  and  cursor   83  (56.1%)  
Digit  Span  (working  memory)   Participants  were  instructed  to  reproduce  sequences  of  numbers,  of  increasing  length,  in  reverse  order.   Maximum  accurately  reproduced  sequence  length   111  (75.0%)  Time  Estimation   Stimuli  (4,  8,  12,  16,  20  seconds)  were  randomly  presented  by  a  lightbulb.  Participants  were  required  to  reproduce  stimulus  length  by  pressing  a  button.  
Absolute  discrepancy  between  the  response  length  and  the  stimulus  length  averaged  across  all  12-­‐second  trials.  
83  (56.1%)  
Motor  Timing   Participants  were  instructed  to  produce  a  1-­‐second  interval  after  a  tone,  as  accurately  as  possible.  Visual  feedback  was  given,  indicating  whether  the  response  was  correct,  too  short  or  too  long  (defined  by  a  dynamic  tracking  algorithm).  
Median  absolute  deviation  in  ms  from  1  second   88  (59.5%)  
n  =  number  of  participants  with  ADHD  who  completed  the  task  at  baseline  and  at  follow-­‐up.       
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